Evidence map›Paper›PMID 40689047›Full record

ArticleAmerican heart journal plus : cardiology research and practice2025

CT derived ECV in severe aortic stenosis: prognosticator and screening test for co-existent transthyretin cardiac amyloidosis.

Joshua N McShane, Anahita Tavoosi, Huda El Mais, Keren Mbondo Kasuku, Anthony Poulin, Mehmet Onur Omaygenc, Ian G Burwash, David Messika-Zeitoun, Benjamin J W Chow, Gary R Small

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joshua N McShaneDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Anahita TavoosiDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Huda El MaisDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Keren Mbondo KasukuDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Anthony PoulinDepartments of Cardiology and Cardiac Surgery, Quebec Heart and Lung Institute, Laval University, 2725 Chemin Ste-FOY, Quebec City, Quebec G1V 4G5, Canada.
Mehmet Onur OmaygencDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Ian G BurwashDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
David Messika-ZeitounDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Benjamin J W ChowDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.
Gary R SmallDivision of Cardiology, Department of medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prior to transcutaneous aortic valve replacement (TAVR), a CT is performed (TAVR-CT). With modification, the CT exam can measure myocardial extracellular volume (ECV). A small increase in ECV occurs in severe aortic stenosis. A large increase in ECV occurs when transthyretin cardiac amyloidosis (ATTR-CA) co-exists. We sought to determine the prognostic potential of ECV in severe aortic stenosis and test the utility of threshold ECV to instigate screening for ATTR-CA. Methods: This was a prospective observation study of consecutive severe AS patients undergoing CT -TAVR. A delayed cardiac acquisition was acquired 5 min post TAVR-CT. Pre-contrast and delayed -images were used to determine ECV. When ECV ≥ 31 % Results: During the study, 161 patients underwent aortic valve replacement and were included in the analysis. Mean age was 81.6 (±6.2) years. During median follow up of 29 (21-36) months, 24 deaths occurred.In 30 patients ECV ≥ 31 %, 2 had positive Conclusion: In severe AS, elevated ECV was a risk for all cause mortality, but this was not related to co-existent ATTR-CA. Threshold-ECV testing for ATTR-CA demonstrated a low yield. Threshold testing may therefore not be warranted in all severe AS patients with an ECV ≥ 31 %.

Indexed as

Aortic stenosisMyocardial extracellular volumeTransthyretin cardiac amyloidosis

Identifiers

PMID40689047
PMCPMC12272441

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.